Blinatumomab
Bispecific CD19-directed CD3-directed T Cell Engager
Brands
Blinatumomab Injection
| Dosage | Brand | Image |
|---|---|---|
| blinatumomab 0.035 MG Injection | Generic | |
| blinatumomab 0.035 MG Injection [Blincyto] | Generic |
Blinatumomab drug classes:
- Bispecific CD19-directed CD3-directed T Cell Engager
Blinatumomab pharmacologic actions:
- Antineoplastic Agents
Blinatumomab mechanism of action:
- CD3 Receptor Agonists
- CD19-directed Antibody Interactions
- CD3-directed Antibody Interactions
